Beth Ann Smith - 12 Feb 2026 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
VP, Controller & Treasurer
Signature
/s/ Beth Smith
Issuer symbol
MGNX
Transactions as of
12 Feb 2026
Net transactions value
-$723
Form type
4
Filing time
17 Feb 2026, 18:26:26 UTC
Previous filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Smith Beth Ann VP, Controller & Treasurer 9704 MEDICAL CENTER DRIVE, ROCKVILLE /s/ Beth Smith 17 Feb 2026 0002051299

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise +1,095 +9% 13,204 15 Feb 2026 Direct F1
transaction MGNX Common Stock Tax liability $723 -423 -3.2% $1.71 12,781 15 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Restricted Stock Unit Options Exercise $0 -1,095 -100% $0.000000 0 15 Feb 2026 Common Stock 1,095 Direct F1
transaction MGNX Restricted Stock Unit Award $0 +15,625 $0.000000 15,625 12 Feb 2026 Common Stock 15,625 Direct F2
transaction MGNX Employee Stock Option (right to buy) Award $0 +93,750 $0.000000 93,750 12 Feb 2026 Common Stock 93,750 $1.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 15, 2023, the reporting person was granted 3,285 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.
F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.
F3 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.